Recently Published Articles
  • 2019, August

    original research

    Self-Adjuvanting Peptide Vaccines Against Cervical CancerOpen Access

    PDF603.54 KB 603.54 KB
    Full-Text (HTML)
    Abstract [+]

    Background

    Cervical cancer is a common cause of cancer-related deaths in women worldwide, with a fatality rate second only to breast cancer. Human papillomaviruses (HPVs) are the main causative agents of cervical cancer, and are therefore obvious targets for vaccine development. Although two prophylactic HPV vaccines have been commercialized, therapeutic vaccines against HPVs have not been developed yet. Current vaccine technologies emphasize the power of small particles in targeting immune cells, and particles of 20-50 nm have been reported to induce optimal immune responses against a variety of pathogens and cancers.

    Methods

    We synthesized new nanoparticle-based vaccines against cervical cancer by using antigenic 8Qmin peptide epitope derived from HPV-16 E7 protein, a hydrophilic poly-(L-glutamic acid) (PGA) linker, and an 8-arm poly (tert-butyl acrylate) dendrimer-based delivery system (D8).

    Results

    Four different peptides containing 8Qmin and PGA of different lengths were successfully synthesized with high yield and purity. These were then conjugated to alkyne-functionalized D8 by copper-catalyzed alkyne-azide cycloaddition “click” reaction. The conjugates self-assembled into nanoparticles, with decreased particle size corresponding to a greater number of Glu units. The four vaccine candidates were tested in C57 black 6 (C57BL/6) mice bearing well-established (7-day-old) tumors to examine their therapeutic effects.

    Conclusion

    Interestingly, only one conjugate delayed tumor growth, and montanide adjuvanted antigen, used as a positive control, failed to demonstrate any therapeutic effect.

    Keywords

    Peptide-based subunit vaccine; Human papillomavirus; Polyglutamic acid; Therapeutic cancer vaccine; Polymer-peptide conjugate; Self-adjuvanting; Cervical cancer.


About the Journal

Vaccination Research – Open Journal (VROJ) is an online open access domain designed to facilitate vaccine administration and to safeguard the immune system for protection from various illnesses.

Vaccination is the process of introducing antigen material into a person’s system so as to develop immunity against a particular pathogen. Vaccination is the most effective way to prevent infectious diseases.

Openventio is dedicated to act as an open source for vaccination and immunization techniques, procedures and post-vaccination health care.

Aims and Scope

Vaccination – Open Journal is a peer-reviewed journal that aims to be a complete and reliable source of discoveries and publications in the form of original, articles, review articles, case reports, and new vaccine technologies introduced in this field.

VROJ covers a wide array of subjects as given below:

  • Vaccine safety protocols
  • Advances in vaccination technology
  • Vaccination development, testing and regulation
  • Clinical evaluations and outcomes
  • Adjuvant in vaccine development
  • Legal aspects of vaccination
  • Public health programs and outcomes
  • Vaccination educations and training
  • Immunization
  • Vaccine administration
  • Vaccination research: Bacterial, viral, parasitic and non-infectious diseases

Openventio aims to encourage documentation among the ever growing medical community to ensure that the data gets recorded and passed on to the future generation of practitioners.

Submissions for this journal are accepted from all practitioners, students from experts in the field to novices looking forward to exploring vaccination research.

The audience of VROJ includes doctors, nurses, research assistants, local community practitioners, manufacturers, and students of various universities and general communities from different parts of the world.

The journal welcomes all types of articles such as original research, review, case-report, mini-review, editorial, short-communication, book review, opinion, commentary, letter to the editor, conference proceedings, technical report, errata, illustrations, etc.

We are open to receive your comments or corrections to improve the quality of our journal.